We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
24 June 2019
On 8 May 2019 Justice Roy dismissed Servier's application for a prohibition order under the pre-amended Patented Medicines (Notice of Compliance) Regulations for Canadian Patent 2,423,825 (the 825 Patent) regarding a perindopril arginine/amlodipine product (Servier's Viacoram).(1) Apotex had alleged that the patent was invalid for:
The 825 Patent claimed the arginine salt of perindopril and its hydrates.
The Federal Court held that the allegations of inutility and insufficiency were not justified. However, Roy dismissed the application, finding that Apotex's allegations of obviousness and overbreadth were justified. With respect to overbreadth, the court construed the claims to include all forms of arginine and its hydrates, whereas the inventors:
Based on these findings, Roy found that Servier had not discharged its burden of disproving the allegation that the claims were broader than the invention. With respect to obviousness, the court found that arginine salts were known, and that a skilled person would have known that a structured salt screen conducted to search for a solution to the stability issues of the known salt, perindopril erbumine, would have been available by the filing date.
For further information on this topic please contact Katie Lee at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
(1) Les Laboratoires Servier v Apotex Inc, 2019 FC 616.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.